Genomics Companies

Tempus AI

Chicago, United States

Tempus provides a platform combining comprehensive clinical and molecular data with artificial intelligence, primarily serving the oncology space. Their core offering is an operating system built upon the world’s largest library of such data, enhanced by recent advancements in generative AI like their clinical co-pilot, David, and digital pathology capabilities acquired through Paige. Tempus targets physicians, pharmaceutical companies, and patients seeking data-driven insights to improve cancer treatment decisions and accelerate drug development.

iCarbonX

Shenzhen, China

iCarbonX develops a comprehensive digital health platform, utilizing its core product, the iCarbonX Apollo system, to integrate multi-omics data – including genomics, metabolomics, and microbiome analysis – with data from wearable sensors and user-reported health information. Their AI capabilities focus on developing predictive models for disease risk assessment and personalized health management, leveraging deep learning algorithms to identify biomarkers and patterns indicative of early-stage health concerns. Initially focused on the Chinese market, iCarbonX aims to provide preventative healthcare solutions and has notably partnered with hospitals and research institutions to validate its AI-driven health insights.

Verge Genomics

San Francisco, United States

Verge Genomics has developed CONVERGE®, an AI-powered drug discovery platform utilizing a large, proprietary human multi-omics database to identify and validate drug candidates for neurodegenerative diseases. Their platform leverages machine learning to analyze human tissue data, enabling the rapid identification of novel targets and accelerating drug development – most notably, their lead compound VRG50635, a PIKfyve inhibitor for ALS, entered clinical trials just four years after initial research. Currently focused on ALS, Parkinson’s Disease, and Frontotemporal Dementia, Verge aims to deliver breakthrough treatments for diseases with limited or no effective therapies.

Sidra Medicine leverages artificial intelligence to advance precision medicine, specifically focusing on genomic data analysis for rare disease diagnosis and pediatric applications. Their AI capabilities include machine learning models applied to whole-genome sequencing data, aiding in the identification of genetic variants linked to childhood illnesses and informing personalized treatment strategies. As a leading healthcare provider in Qatar, Sidra Medicine utilizes these technologies to improve patient outcomes and supports regional advancements in pediatric emergency care, demonstrated by their ongoing organization of the Qatar Pediatric Emergency Medicine International Conference (QPEM).